Apotex Health Corp Earnings Recaps
Q1 2027
Aug 15, 2026
Apotex shares declined 4.0% following the quarter as investors reacted to cautious fiscal 2027 guidance coupled with deceleration in U.S. revenues and uncertainty around product launch timing, undermining growth expectations.
Key takeaways
- Reported revenue grew approximately 2% year-over-year on a comparable basis, driven by 11% growth in Canada, notably from semaglutide demand and recent launches.
- U.S. revenue represented 43% of sales but showed signs of deceleration due to halted production on the OPTHA 2 line and delayed FDA reinspection of new sterile manufacturing capacity.
- Full-year guidance was introduced for upper mid-single-digit revenue growth excluding legacy product impacts, with adjusted EBITDA margin around 30%, reflecting a cautious outlook amid operational headwinds.
- Product launch cadence remains critical, with timing risks highlighted by the absence of this year’s nilotinib launch compared to last year’s first-to-file, postponed to Q3.
- Operational execution included $800 million debt reduction and ongoing productivity initiatives targeting over $100 million savings, but margin expansion appears constrained in the near term.